


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. McLaren Oakland</p> <p>2. 50 N. Perry St. Pontiac, MI 48342</p>		<p>In accordance with letter dated August 29, 2017.</p> <p>3. License number: 21-04081-03 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: June 30, 2024</p> <p>5. Docket No.: 030-02041 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

21-04081-03

Docket or Reference Number

030-02041

Amendment No. 60

(Corrected Copy)

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| D. Iodine-125 permitted by 10 CFR 35.400 | D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251; Best Medical International, Inc. (formerly Best Industries, Inc.), Model 2301; Medi-Physics, Inc. d/b/a GE Healthcare/Model 6733 (EchoSeed) and 6711 (OncoSeed); Theragenics Corporation, Model I-Seed 125.S06 and I-Seed AgX100) | D. 600 millicuries total | D. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| E. Palladium-103 permitted by 10 CFR 35.400 | E. Sealed Sources (Best Medical International, Inc. (formerly Best Industries, Inc.), Model 2335; Theragenics Corporation, Model TheraSeed 200) | E. 600 millicuries total | E. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |

CONDITIONS

10. A. Licensed material listed in Subitem Nos. 6.A. through 6.E. may be used at the licensee's facilities located at 50 N. Perry St., Pontiac, Michigan 48058.
- B. Licensed material listed in Subitem Nos. 6.A. through 6.C. may be used at McLaren Oakland Clarkston Radiology, 6770 Dixie Hwy., Clarkston, Michigan 48346.
- C. Licensed material listed in Subitem No. 6.B. (for sentinel node injections only) may also be used or stored at the licensee's facilities located at McLaren Diagnostic Imaging, 5701 Bow Pointe Dr., Clarkson, Michigan 48346.
- D. Licensed material listed in Subitem Nos. 6.A. and 6.B. may be used at the licensee's facilities located at McLaren Oakland Outpatient Services, 5625 Water Tower Plaza, Clarkston, MI 48346.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
21-04081-03

Docket or Reference Number
030-02041

Amendment No. 60
(Corrected Copy)

11. The Radiation Safety Officer (RSO) for this license is Kenneth P. Tarr, D.O.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Arthur J. Frazier, M.D.

10 CFR 35.300,10 CFR 35.400

Stephen D. Franklin, M.D.

10 CFR 35.400

Kenneth P. Tarr, D.O.


10 CFR 35.100,10 CFR 35.200

Adam R. Schwaderer, D.O.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Kevin R. Carter, D.O.

10 CFR 35.100,10 CFR 35.200,10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-04081-03Docket or Reference Number
030-02041Amendment No. 60
(Corrected Copy)

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated January 16, 2014 (ML14021A094)
 - B. Letter dated June 27, 2016 (ML16183A331)
 - C. Letter dated August 19, 2016 (ML16242A198)
 - D. Letter dated July 11, 2017 (ML17195A051)
 - E. Letter dated August 14, 2017 (ML17233A023)
 - F. Letter dated August 29, 2017 (ML17248A232)
 - G. Letter dated September 13, 2017 (ML17269A050)
 - H. Letter dated October 10, 2017 (ML17284A209)
 - I. Letter dated November 2, 2017 (ML17310A569)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: MAR 13 2018By: Bryan A. Parker
Region III